CN108888762A - A kind of composition of the metabolite containing probiotics - Google Patents
A kind of composition of the metabolite containing probiotics Download PDFInfo
- Publication number
- CN108888762A CN108888762A CN201810929946.4A CN201810929946A CN108888762A CN 108888762 A CN108888762 A CN 108888762A CN 201810929946 A CN201810929946 A CN 201810929946A CN 108888762 A CN108888762 A CN 108888762A
- Authority
- CN
- China
- Prior art keywords
- metabolite
- probiotics
- yolk
- composition
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 67
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 67
- 239000002207 metabolite Substances 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 83
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 48
- 239000007788 liquid Substances 0.000 claims abstract description 41
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 30
- 208000015181 infectious disease Diseases 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 19
- 241000700605 Viruses Species 0.000 claims description 30
- -1 polypropylene Polymers 0.000 claims description 27
- 206010012735 Diarrhoea Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 102000002322 Egg Proteins Human genes 0.000 claims description 20
- 108010000912 Egg Proteins Proteins 0.000 claims description 20
- 235000013345 egg yolk Nutrition 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 13
- 230000002458 infectious effect Effects 0.000 claims description 13
- 241000702670 Rotavirus Species 0.000 claims description 12
- 235000013601 eggs Nutrition 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 10
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 9
- 239000004695 Polyether sulfone Substances 0.000 claims description 9
- 239000004743 Polypropylene Substances 0.000 claims description 9
- 239000004744 fabric Substances 0.000 claims description 9
- 229920006393 polyether sulfone Polymers 0.000 claims description 9
- 229920001155 polypropylene Polymers 0.000 claims description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 8
- 229930182830 galactose Natural products 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- 238000010612 desalination reaction Methods 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 244000063299 Bacillus subtilis Species 0.000 claims description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 5
- 241000194033 Enterococcus Species 0.000 claims description 5
- 208000005577 Gastroenteritis Diseases 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 235000019270 ammonium chloride Nutrition 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000005057 refrigeration Methods 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 241000194108 Bacillus licheniformis Species 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 229940099112 cornstarch Drugs 0.000 claims description 2
- 235000020247 cow milk Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 abstract description 9
- 238000009395 breeding Methods 0.000 abstract description 9
- 230000001488 breeding effect Effects 0.000 abstract description 9
- 239000002699 waste material Substances 0.000 abstract description 9
- 241000588724 Escherichia coli Species 0.000 abstract description 5
- 241000607142 Salmonella Species 0.000 abstract description 5
- 241000711484 Transmissible gastroenteritis virus Species 0.000 abstract description 5
- 241000193468 Clostridium perfringens Species 0.000 abstract description 4
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 abstract description 4
- 241000702665 Porcine rotavirus Species 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 description 24
- 238000012360 testing method Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of compositions of metabolite containing probiotics, including probiotics metabolite 1-10 parts by weight, oligosaccharide 2-3 parts by weight, the powder containing Yolk antibody or liquid 3-8 parts by weight.Compared with prior art, the present invention have can reduce waste discharge, turn waste into wealth, the property of can choose inhibits pathogenic bacteria breeding, for preventing or treating alimentary infection caused by escherichia coli of piglets, salmonella, C.perfringens, transmissible gastro-enteritis virus, Porcine epidemic diarrhea virus, porcine rotavirus etc..
Description
Technical field
The invention belongs to field of biotechnology, and in particular to a kind of composition of the metabolite containing probiotics.
Background technique
Piglet digestive infection is to seriously threaten piglet health, a kind of disease of survival rate, although alimentary canal infection is opposite
It is easier to treat in other diseases, but because its pathogen is widely present, and the suckling pig immune system being just born is not perfect, supports
Drag is low, so morbidity is universal, according to incompletely statistics, piglet disease incidence may be up to 80% or more.
Bacillary alimentary canal infection main pathogens are Escherichia coli, salmonella etc., and there are many antibacterials on the market
For the treatment of this kind of disease, and effect is also ideal, but drug resistance also easily occurs in Reusability.There are also a kind of living simultaneously
Bacteria preparation is also used for bacillary alimentary canal infection, and this kind of active bacteria formulation main component is bacillus, lactic acid bacteria, enterococcus etc.
Beneficial bacteria of intestinal tract is bred after taking orally in animal gastrointestinal tract, so that pathogenic bacteria be inhibited to breed, does not have to worry medicine after this preparation use
Object residual does not have to worry the negative factors such as drug resistance, but to environmental requirement height when this kind of formulation storage, and cannot be with it when use
He has the drug of antibacterial activity to be used in conjunction with.
Viral alimentary canal infection main pathogens have transmissible gastro-enteritis virus, Porcine epidemic diarrhea virus, pig wheel
Shape virus.It is temporarily available without special efficacy chemicals in the market for this kind of viral infection, can only by vaccine immunity, but
It is that will can be used without specific medicament if immuning failure, or the Blank immunization phase after being immunized before generation antibody are infected.
Currently, many breeding enterprises in China, especially small-sized farm and family-raise field, do not have differentiation bacterium also
Property alimentary canal infection and viral alimentary canal infection technical conditions, once morbidity, can only be diagnosed by limited experience and
Treatment, misdiagnosis rate is high, and therapeutic effect is also undesirable.
It is limited by above-mentioned condition, although animal digestive canal infection is not difficult to treat, but damage caused by breeding enterprise, raiser
It loses very serious.
Application No. is 201010517427.0 technical solutions, provide a kind of lactobacillus reuteri and its compound viable bacteria system
Agent, the active bacteria formulation are remarkably improved weanling pig head daily gain and feed efficiency, reduce as feed addictive after feeding
Grice diarrhoea rate, increases economic efficiency.But there are certain defects in storage and use for the active bacteria formulation, to ring during storage
Border requires height, and temperature, moisture etc. are possible to that number of viable is caused to reduce, and curative effect is caused to decline, and said preparation is because containing work
Bacterium can be killed by antibiotic ingredient or reduce effectiveness and cannot be used in mixed way with other drugs with antibacterial activity, this meeting
Trouble is caused to clinical application, increases cost.
Summary of the invention
It is an object of the present invention to overcome the above-mentioned drawbacks of the prior art and provide one kind to prevent and treat
Piglet bacterial, viral infection the metabolite containing probiotics composition.
The purpose of the present invention can be achieved through the following technical solutions：A kind of composition of the metabolite containing probiotics,
It is characterised in that it includes probiotics metabolite 1-10 parts by weight, oligosaccharide 2-3 parts by weight, powder or liquid containing Yolk antibody
Body 3-8 parts by weight.
The probiotics metabolite is Bacillus acidi lactici metabolite, Bifidobacterium metabolite, enterococcus metabolism production
One of object, bacillus subtilis metabolite, bacillus licheniformis metabolite, metabolism of yeasts product are a variety of, excellent
Select Bacillus acidi lactici metabolite, Bifidobacterium metabolite, enterococcus metabolite by 1:1:1 isometric mixing.
The probiotics metabolite is made by the following method：It is 0.2 μm by aperture for probiotics fermention liquid to gather
Propylene microcellular filter filtration sterilization, filtrate, which passes through again in the polyether sulfone that molecular cut off is 10KD, controls fabric filter ultrafiltration,
Desalination, dehydration, concentration and be made.Wherein probiotics fermention liquid is the hair that the above-mentioned published fermentation process of various probiotics uses
Zymotic fluid, or be commercially available probiotics fermention liquid.
The oligosaccharide is isomalto-oligosaccharide, fructose oligosaccharides, sucrose oligosaccharide, cow's milk oligosaccharide, soy oligosaccharides
One or more of sugar, galactose oligosaccharides.The molecular weight ranges 200~2000 of oligosaccharide, preferably isomalto-oligosaccharide, fruit
Sugared oligosaccharide, sucrose oligosaccharide, galactose oligosaccharides in mass ratio 1:1:1:1 oligosaccharide mixture being mixed into.
In the powder or liquid containing Yolk antibody Yolk antibody be anti-swine infectious enterogastritis virus Yolk antibody,
Porcine epidemic diarrhea resisting virus Yolk antibody or anti-porcine rotavirus Yolk antibody.
Described powder or liquid containing Yolk antibody is made by the following method：Healthy laying hen is selected, is infected using pig
Property marcy agent-Porcine epidemic diarrhea virus-pig colyliform disease triple vaccine carry out reinforced immunological, every 10 days are 1 time immune, continuously exempt from
It carries out remaining immune after epidemic disease 3 times, every 15 days 1 time, detects anti-swine infectious enterogastritis virus respectively using ELIISA method, anti-pig is flowed
Row diarrhea virus, anti-porcine rotavirus Yolk antibody potency, when potency >=128 when start collect egg, collect egg yolk liquid,
Yolk powder or Yolk antibody concentrate containing Yolk antibody is made.
Egg yolk liquid is collected, salt is added, adds 2~4 times of volume purified waters of egg yolk liquid, stirs evenly, 1~10 DEG C of refrigeration
24~48 hours are stood, 3000~5000prm centrifugation, 0.2 μm of polypropylene microporous filter filtering, molecular cut off is 10KD's
Fabric filter ultrafiltration is controlled in polyether sulfone, and Yolk antibody concentrate is made.
The salt being added in the egg yolk liquid is one of calcium oxalate, sodium alginate, ammonium chloride, sodium chloride, calcium chloride
Or it is a variety of, the mass ratio of egg yolk liquid and salt is 100:1~1000:1.
When potency >=128 when start to collect egg, collect the egg yolk liquid of egg, be uniformly mixed, 75~100 DEG C are spraying dry
It is dry at yolk powder.
The composition of the above-mentioned metabolite containing probiotics can be processed into solution, paste, pulvis etc. by conventional technique
It is applicable in dosage form.
The composition of the above-mentioned metabolite containing probiotics for prevent, treat for prevent or treat escherichia coli of piglets,
Caused by salmonella, C.perfringens, transmissible gastro-enteritis virus, Porcine epidemic diarrhea virus, porcine rotavirus etc.
Alimentary infection.
It can also include cornstarch, sodium carboxymethylcellulose, PVP-K in the composition of the above-mentioned metabolite containing probiotics
One of, it is used as carrier or thickening.
Probiotics metabolite used in this programme is separated from the culture after probiotics for pigs fermentation.After probiotics fermention
Target product be probiotics, the culture solution after probiotics filtering and concentrating is waste, but many of culture solution ingredient has
Utility value, such as enzyme, organic acid, Antibacterial Constituents, vitamin etc., these ingredients can produce more after being utilized by piglet
Kind effect, what this programme to be utilized is its Antibacterial Constituents, is to act on produced by probiotics probiotics unrestraint,
But there is inhibiting effect to pathogenic bacteria.
Oligosaccharide selected by this programme can be utilized by beneficial bacteria of intestinal tract such as Bifidobacterium, Bacillus acidi lacticis, provide battalion for it
It supports, but cannot be utilized by pathogenic bacteria such as Escherichia coli, salmonella, C.perfringens, probiotics can be promoted to breed, from
And inhibit pathogenic bacteria quantity；Oligosaccharide can also inhibit pathogenic bacteria by spoilage products such as amino acid converting generation ammonia, indoles simultaneously,
Spoilage product is reduced to the toxic side effect to animal intestines and stomach mucous membrane.
Anti-swine infectious enterogastritis virus Yolk antibody, porcine epidemic diarrhea resisting virus yolk required by this programme are anti-
Body, anti-porcine rotavirus Yolk antibody, can be directly sick with transmissible gastro-enteritis virus, Porcine epidemic diarrhea virus, pig colyliform
Poison is immunoreacted, it is inhibited to breed duplication in pig body.
Compared with prior art, the technical program has the characteristics that：
1, probiotics metabolite is separated from the waste after probiotics fermention, can reduce waste discharge.
2, the Antibacterial Constituents alternative in probiotics metabolite inhibits pathogenic bacteria breeding, does not inhibit probiotics numerous
It grows, can effectively prevent or treat escherichia coli of piglets, salmonella, C.perfringens, transmissible gastro-enteritis virus, pig
Alimentary infection caused by epidemic diarrhea virus, porcine rotavirus etc.；And conventional antibacterial drugs can inhibit to cause without selectivity
Germ reproduction can also inhibit probiotics to breed.
3, for oligosaccharide as probiotics nutritional ingredient, alternative promotes the breeding of gastrointestinal tract probiotics, to inhibit to cause a disease
Bacterium breeding is to promote originality probiotics breeding in gastrointestinal tract by supplementing the nutrients；And conventional probiotic products are active bacteria formulation, mouth
It is colonized after clothes in gastrointestinal tract, so that pathogenic bacteria be inhibited to breed, is that it is promoted to breed in gastrointestinal tract by probiotic supplemented, compares it
Under, the former more has apparent advantage：
1) bacterial screening, fermentating breeding is omitted, viable bacteria is collected and a series of complex processes such as preparation.
2) it avoids strain and colonizes the risks such as failure, breeding undesirable and pathogenic bacteria pollution in gastrointestinal tract.
4, viable bacteria ingredient is free of in preparation, quality is more stable, is easier to store, and can be used cooperatively with other antibiotic preparations；
And conventional probiotics preparation is because of ingredient containing viable bacteria, requires height, and unstable quality to storage condition, when clinical use should not with resist
Bacteria preparation is used cooperatively.
5, directly with pathogen immune response can occur for Yolk antibody and making it no longer has pathogenecity, be suitble to immune
The treatment of failure and Blank immunization phase cases of infection, especially viral infection.
6, obtained preparation does not have to add any preservative, and probiotics metabolite has antibacterial anti-corrosion function.
Specific embodiment
It elaborates below to the embodiment of the present invention, the present embodiment carries out under the premise of the technical scheme of the present invention
Implement, the detailed implementation method and specific operation process are given, but protection scope of the present invention is not limited to following implementation
Example.
Embodiment 1
A kind of composition of the metabolite containing probiotics, is mainly resisted by pig beneficial bacteria of intestinal tract metabolite, oligosaccharide, yolk
Body composition.
The probiotics metabolite is Bacillus acidi lactici metabolite, Bifidobacterium metabolite, enterococcus metabolite.
Waste liquid after three kinds of probiotics fermention liquid to be recycled to viable bacteria presses 1:1:1 isometric mixing, is 0.2 μm of polypropylene microporous by aperture
Filter filtration sterilization, filtrate passes through again controls fabric filter ultrafiltration in the polyether sulfone that molecular cut off is 10KD, desalination takes off
Water is concentrated to original volume 1/10, spare.
The oligosaccharide is isomalto-oligosaccharide, fructose oligosaccharides, sucrose oligosaccharide, galactose oligosaccharides in mass ratio 1:
1:1:1 oligosaccharide mixture being mixed into.
The Yolk antibody is anti-swine infectious enterogastritis virus Yolk antibody, porcine epidemic diarrhea resisting virus yolk is anti-
Body, anti-porcine rotavirus Yolk antibody, production technology are as follows：Healthy laying hen is selected, is flowed using transmissible gastro-enteritis virus-pig
Row diarrhea virus-pig colyliform disease triple vaccine carries out reinforced immunological, carries out maintaining to exempt from after being immunized 1 time, continuous immunity 3 times within every 10 days
Epidemic disease, every 15 days 1 time.Anti-swine infectious enterogastritis virus, porcine epidemic diarrhea resisting virus, anti-pig are detected respectively using ELIISA method
Rotavirus Yolk antibody potency, when >=128 when start collect egg.Egg yolk liquid is collected, is uniformly mixed, 85 DEG C of spray drying
At yolk powder.
Above-mentioned probiotics metabolite concentrate 10kg, oligosaccharide mixture 2.5kg, yolk powder 5kg are taken, carrier corn forms sediment
Powder 2.5kg is uniformly mixed, 45 DEG C fluidized drying 10 minutes, cross 40 meshes, sealed package is spare.
Embodiment 2
A kind of composition of the metabolite containing probiotics, is mainly resisted by pig beneficial bacteria of intestinal tract metabolite, oligosaccharide, yolk
Body composition.
The probiotics metabolite is Bacillus acidi lactici metabolite, Bifidobacterium metabolite, bacillus subtilis generation
Thank product, bacillus licheniformis metabolite.Waste liquid after four kinds of probiotics fermention liquid to be recycled to viable bacteria presses 1:1:1:1 is isometric
Mixing, is 0.2 μm of polypropylene microporous filter filtration sterilization by aperture, and filtrate passes through the polyethers that molecular cut off is 10KD again
Fabric filter ultrafiltration is controlled in sulfone, desalination, dehydration are concentrated to original volume 1/10, spare.
The oligosaccharide is isomalto-oligosaccharide, fructose oligosaccharides, sucrose oligosaccharide, galactose oligosaccharides in mass ratio 1:
2:2:1 oligosaccharide mixture being mixed into.
The Yolk antibody is anti-swine infectious enterogastritis virus Yolk antibody, porcine epidemic diarrhea resisting virus yolk is anti-
Body, anti-porcine rotavirus Yolk antibody, production technology are as follows：Healthy laying hen is selected, is flowed using transmissible gastro-enteritis virus-pig
Row diarrhea virus-pig colyliform disease triple vaccine carries out reinforced immunological, carries out maintaining to exempt from after being immunized 1 time, continuous immunity 3 times within every 10 days
Epidemic disease, every 15 days 1 time.Anti-swine infectious enterogastritis virus, porcine epidemic diarrhea resisting virus, anti-pig are detected respectively using ELIISA method
Rotavirus Yolk antibody potency, when >=128 when start collect egg.Egg yolk liquid is collected, is uniformly mixed, 85 DEG C of spray drying
At yolk powder.
Above-mentioned probiotics metabolite concentrate 4kg, oligosaccharide mixture 2kg, yolk powder 3kg are taken, agent carboxymethyl is thickened
Sodium cellulosate 1kg is uniformly mixed, and refiner stirs 15 minutes, and the uniform paste of quality is made, spare.
Embodiment 3
A kind of composition of the metabolite containing probiotics, is mainly resisted by pig beneficial bacteria of intestinal tract metabolite, oligosaccharide, yolk
Body composition.
The probiotics metabolite is Bacillus acidi lactici metabolite, Bifidobacterium metabolite, bacillus subtilis generation
Thank product, metabolism of yeasts product.Waste liquid after four kinds of probiotics fermention liquid to be recycled to viable bacteria presses 2:2:1:1 isometric mixing,
It is 0.2 μm of polypropylene microporous filter filtration sterilization by aperture, filtrate passes through again in the polyether sulfone that molecular cut off is 10KD
Fabric filter ultrafiltration is controlled, desalination, dehydration are concentrated to original volume 1/20, spare.
The oligosaccharide is fructose oligosaccharides, galactose oligosaccharides in mass ratio 1:1 oligosaccharide mixture being mixed into.
The Yolk antibody is anti-swine infectious enterogastritis virus Yolk antibody, porcine epidemic diarrhea resisting virus yolk is anti-
Body, anti-porcine rotavirus Yolk antibody, production technology are as follows：Healthy laying hen is selected, is flowed using transmissible gastro-enteritis virus-pig
Row diarrhea virus-pig colyliform disease triple vaccine carries out reinforced immunological, carries out maintaining to exempt from after being immunized 1 time, continuous immunity 3 times within every 10 days
Epidemic disease, every 15 days 1 time.Anti-swine infectious enterogastritis virus, porcine epidemic diarrhea resisting virus, anti-pig are detected respectively using ELIISA method
Rotavirus Yolk antibody potency, when >=128 when start collect egg.Egg yolk liquid is collected, by egg yolk liquid and sodium alginate
Mass ratio is 1000：1 is added sodium alginate, adds 4 times of volume purified waters of egg yolk liquid, stirs evenly, and 5 DEG C of refrigerations stand 24
Hour, 5000prm centrifugation takes 0.2 μm of polypropylene microporous filter filtering of supernatant, and molecular cut off is in the polyether sulfone of 10KD
Fabric filter ultrafiltration is controlled, the 1/20 of total volume is concentrated to, obtains Yolk antibody concentrate, it is spare.
Above-mentioned probiotics metabolite concentrate 1.5kg, oligosaccharide mixture 2kg, Yolk antibody concentrate 8kg are taken, is increased
Thick dose of PVP-K30 0.15kg, after stirring is completely dissolved plus purified water constant volume is to 10L, and the uniform solution of quality is made, spare.
Embodiment 4
The prepared pulvis of Example 1,10% colistin sulphate soluble powder carry out clinical test.Weanling pig turns group
When select weanling pig totally 90, be divided into 3 groups at random：Test group, positive controls and negative control group.In test group feed
By 2:98 mass ratio adds the prepared pulvis of embodiment 1 into feed, presses 2 in positive controls feed:98 mass ratio to
10% colistin sulphate soluble powder is added in feed, does not add any ingredient in negative control group feed.Three groups of experimental animals
It is raised in identical environment, the test period is 10 days, concentrates medication 5 days, then observes 5 days.Each group is once sent out in experimental period
Now dysentery diarrhea case, that is, be isolated and separately treat, and records in detail, as a result counts as follows：
| Group | Experimental animal (head) | Affected animal (head) | Disease incidence (%) |
| Test group | 30 | 5 | 16.67 |
| Positive group | 30 | 6 | 20.00 |
| Negative group | 30 | 17 | 56.67 |
It, can from the above test data it is found that test group, positive group organize intercurrent disease rate significant difference (P < 0.05) with negative
See when piglet turns group that alimentary canal the incidence of infection is higher, the prepared pulvis of embodiment 1 and 10% sulfuric acid slime mould because of environmental change
Plain soluble powder can be effectively controlled.
Embodiment 5
The prepared paste of Example 2,1% neomycin sulphate solution carry out clinical test.With 3 days in same delivery room
Age piglet is that subjects carry out above-mentioned experiment：Test group animal 42, every piglet gavages the prepared paste 2ml of embodiment 2；
Positive controls animal 42, every piglet gavages 1% neomycin sulphate solution 2ml；It negative control group animal 42, does not use
Any chemoprophylaxis.It is observed continuously after medication 5 days, and records each group yellowish-white dysentery incidence in detail.As a result it counts as follows：
| Group | Experimental animal (head) | Affected animal (head) | Disease incidence (%) |
| Test group | 42 | 3 | 7.14 |
| Positive group | 42 | 4 | 9.52 |
| Negative group | 42 | 26 | 61.90 |
It, can from the above test data it is found that test group, positive group organize intercurrent disease rate significant difference (P < 0.05) with negative
See that the matched paste of embodiment 2 and 1% neomycin sulphate solution are significant to piglet yellow-white dysentery preventive effect.
Embodiment 6
The prepared paste of Example 2,1% neomycin sulphate solution carry out clinical test, and test period is viral
Diarrhea epidemic season.Above-mentioned experiment is carried out by subjects of the child care piglet in same nursery house：Test group animal 31, often
Head piglet gavages the prepared solution 5ml of embodiment 3；Positive controls animal 31, it is molten that every piglet gavages 1% neomycinsulphate
Liquid 5ml；Negative control group animal 30, any chemoprophylaxis is not used.Test period be 15 days, each group continuous use 5 days, 1
Times/day, it then observes, and record each group diarrhea incidence in detail.As a result it counts as follows：
| Group | Experimental animal (head) | Affected animal (head) | Disease incidence (%) |
| Test group | 31 | 5 | 16.13 |
| Positive group | 31 | 16 | 51.61 |
| Negative group | 31 | 22 | 70.96 |
It, can from the above test data it is found that test group and positive group, feminine gender organize intercurrent disease rate significant difference (P < 0.05)
See that the matched solution of embodiment 3 is significant to virus diarrhea preventive effect, and 1% neomycin sulphate solution prevents virus diarrhea
Effect is undesirable.
Embodiment 7
A kind of composition of the metabolite containing probiotics, is mainly resisted by pig beneficial bacteria of intestinal tract metabolite, oligosaccharide, yolk
Body composition.
The probiotics metabolite is Bacillus acidi lactici metabolite, Bifidobacterium metabolite, bacillus subtilis generation
Thank product, metabolism of yeasts product.Waste liquid after four kinds of probiotics fermention liquid to be recycled to viable bacteria presses 2:2:1:1 isometric mixing,
It is 0.2 μm of polypropylene microporous filter filtration sterilization by aperture, filtrate passes through again in the polyether sulfone that molecular cut off is 10KD
Fabric filter ultrafiltration is controlled, desalination, dehydration are concentrated to original volume 1/20, spare.
The oligosaccharide is fructose oligosaccharides, galactose oligosaccharides in mass ratio 1:1 oligosaccharide mixture being mixed into.
The Yolk antibody is anti-swine infectious enterogastritis virus Yolk antibody, porcine epidemic diarrhea resisting virus yolk is anti-
Body, anti-porcine rotavirus Yolk antibody, production technology are as follows：Healthy laying hen is selected, is flowed using transmissible gastro-enteritis virus-pig
Row diarrhea virus-pig colyliform disease triple vaccine carries out reinforced immunological, carries out maintaining to exempt from after being immunized 1 time, continuous immunity 3 times within every 10 days
Epidemic disease, every 15 days 1 time.Anti-swine infectious enterogastritis virus, porcine epidemic diarrhea resisting virus, anti-pig are detected respectively using ELIISA method
Rotavirus Yolk antibody potency, when >=128 when start collect egg.Egg yolk liquid is collected, by the matter of egg yolk liquid and ammonium chloride
Amount is than being 100：1 is added ammonium chloride, adds 4 times of volume purified waters of egg yolk liquid, stirs evenly, and 5 DEG C of refrigerations stand 24 hours,
5000prm centrifugation takes 0.2 μm of polypropylene microporous filter filtering of supernatant, and molecular cut off is that fibre is controlled in the polyether sulfone of 10KD
Dimensional filter device ultrafiltration, is concentrated to the 1/20 of total volume, obtains Yolk antibody concentrate, spare.
Above-mentioned probiotics metabolite concentrate 1kg, oligosaccharide mixture 3kg, Yolk antibody concentrate 8kg are taken, is thickened
Agent PVP-K30 0.15kg, after stirring is completely dissolved plus purified water constant volume is to 10L, and the uniform solution of quality is made, spare.
The above description of the embodiments is intended to facilitate ordinary skill in the art to understand and use the invention.
Person skilled in the art obviously easily can make various modifications to these embodiments, and described herein general
Principle is applied in other embodiments without having to go through creative labor.Therefore, the present invention is not limited to the above embodiments, ability
Field technique personnel announcement according to the present invention, improvement and modification made without departing from the scope of the present invention all should be of the invention
Within protection scope.
Claims (10)
1. a kind of composition of metabolite containing probiotics, which is characterized in that including probiotics metabolite 1-10 parts by weight, low
Glycan 2-3 parts by weight, the powder containing Yolk antibody or liquid 3-8 parts by weight.
2. the composition of the metabolite according to claim 1 containing probiotics, which is characterized in that the probiotics metabolism
Product be Bacillus acidi lactici metabolite, Bifidobacterium metabolite, enterococcus metabolite, bacillus subtilis metabolite,
One of bacillus licheniformis metabolite, metabolism of yeasts product are a variety of.
3. the composition of the metabolite according to claim 1 containing probiotics, which is characterized in that the probiotics metabolism
Product is made by the following method：It is 0.2 μm of polypropylene microporous filter filtration sterilization, filter that probiotics fermention liquid, which is passed through aperture,
Liquid pass through again molecular cut off be 10KD polyether sulfone in control fabric filter ultrafiltration, desalination, dehydration, concentration and be made.
4. the composition of the metabolite according to claim 1 containing probiotics, which is characterized in that the oligosaccharide is different
One of malto-oligosaccharide, fructose oligosaccharides, sucrose oligosaccharide, cow's milk oligosaccharide, soyabean oligosaccharides, galactose oligosaccharides or
It is several.
5. the composition of the metabolite according to claim 1 containing probiotics, which is characterized in that described contains Yolk antibody
Powder or liquid in Yolk antibody be that anti-swine infectious enterogastritis virus Yolk antibody, porcine epidemic diarrhea resisting virus yolk are anti-
Body or anti-porcine rotavirus Yolk antibody.
6. the composition of the metabolite according to claim 1 containing probiotics, which is characterized in that described contains Yolk antibody
Powder or liquid be made by the following method：Healthy laying hen is selected, transmissible gastro-enteritis virus-pig epidemic diarrhea is used
Virus-pig colyliform disease triple vaccine carries out reinforced immunological, carries out remaining immune after being immunized 1 time, continuous immunity 3 times within every 10 days, every 15
It 1 time, anti-swine infectious enterogastritis virus, porcine epidemic diarrhea resisting virus, anti-pig colyliform disease are detected respectively using ELIISA method
Malicious Yolk antibody potency, when potency >=128 when start collect egg, collect egg yolk liquid, the yolk powder containing Yolk antibody is made
Or Yolk antibody concentrate.
7. the composition of the metabolite according to claim 6 containing probiotics, which is characterized in that collect egg yolk liquid, be added
Salt adds 2~4 times of volume purified waters of egg yolk liquid, stirs evenly, and 1~10 DEG C of refrigeration stands 24~48 hours, 3000~
5000prm centrifugation, 0.2 μm of polypropylene microporous filter filter, and control fabric filter in the polyether sulfone that molecular cut off is 10KD
Yolk antibody concentrate is made in ultrafiltration.
8. the composition of the metabolite according to claim 7 containing probiotics, which is characterized in that add in the egg yolk liquid
The salt entered is one of calcium oxalate, sodium alginate, ammonium chloride, sodium chloride, calcium chloride or a variety of, the mass ratio of egg yolk liquid and salt
It is 100:1~1000:1.
9. the composition of the metabolite according to claim 6 containing probiotics, which is characterized in that when potency >=128 when
Start to collect egg, collect the egg yolk liquid of egg, is uniformly mixed, 75~100 DEG C are spray dried to yolk powder.
10. the composition of the metabolite according to claim 1 containing probiotics, which is characterized in that in the composition
It further include one of cornstarch, sodium carboxymethylcellulose, PVP-K.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810929946.4A CN108888762A (en) | 2018-08-15 | 2018-08-15 | A kind of composition of the metabolite containing probiotics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810929946.4A CN108888762A (en) | 2018-08-15 | 2018-08-15 | A kind of composition of the metabolite containing probiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108888762A true CN108888762A (en) | 2018-11-27 |
Family
ID=64354855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810929946.4A Pending CN108888762A (en) | 2018-08-15 | 2018-08-15 | A kind of composition of the metabolite containing probiotics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108888762A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109385387A (en) * | 2018-12-28 | 2019-02-26 | 上海源耀生物股份有限公司 | The lactobacillus reuteri of anti-TGEV a kind of and its application |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
| CN1663573A (en) * | 2004-03-04 | 2005-09-07 | 青岛东海药业有限公司 | A stable and safe microecological formulation, its preparation and usage |
| CN101099749A (en) * | 2007-07-25 | 2008-01-09 | 上海交大昂立股份有限公司 | Composition containing lactobacillus acidophilus and bidifobacterium longum and application thereof |
| CN101366734A (en) * | 2008-06-18 | 2009-02-18 | 辽宁大生药业有限公司 | Synbiotics medicament composition |
| EP2359858A1 (en) * | 2004-08-24 | 2011-08-24 | N.V. Nutricia | Nutritional composition comprising indigestible oligosaccharides |
| US20120039956A1 (en) * | 2010-08-13 | 2012-02-16 | Moti Harel | Dry storage stabilizing composition for biological materials |
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| CN103893219A (en) * | 2012-12-28 | 2014-07-02 | 瑞普（天津）生物药业有限公司 | Probiotics for preventing and treating pet diarrhea |
| CN104548093A (en) * | 2014-12-22 | 2015-04-29 | 天津瑞普生物技术股份有限公司 | Composition for treating piglet diarrhea and preparation method of composition |
| CN105125972A (en) * | 2015-09-21 | 2015-12-09 | 山西省农业科学院畜牧兽医研究所 | Chinese herbal preparation for improving intestinal microecology and repairing intestinal mucosa injuries of piglets |
| CN106075433A (en) * | 2016-06-17 | 2016-11-09 | 山西纳安生物科技有限公司 | Many targeted nanos antibody polymerization chain junctor that a kind of probiotic bacteria that can be used for treatment of cancer is expressed |
| CN106729706A (en) * | 2015-11-19 | 2017-05-31 | 鼎正生物药业(天津)有限公司 | A kind of immune response regulation medicine based on IgG antibody |
| CN106806892A (en) * | 2015-12-02 | 2017-06-09 | 天津振邦水产养殖有限公司 | A kind of gut flora regulating drug based on Yolk antibody |
| CN107296164A (en) * | 2017-07-19 | 2017-10-27 | 东北农业大学 | A kind of preparation method for the Traditional Chinese medicine probiotic fermentating metabolism product for preventing and treating piglet bacillary diarrhoea |
| CN107921113A (en) * | 2015-08-25 | 2018-04-17 | 巴比塔·阿格拉沃尔 | Immunomodulatory compositions and methods of use thereof |
| CN108094726A (en) * | 2017-12-14 | 2018-06-01 | 福建傲农生物科技集团股份有限公司 | A kind of creep feed for enhancing pigling immunity and preparation method and application |
-
2018
- 2018-08-15 CN CN201810929946.4A patent/CN108888762A/en active Pending
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
| CN1663573A (en) * | 2004-03-04 | 2005-09-07 | 青岛东海药业有限公司 | A stable and safe microecological formulation, its preparation and usage |
| EP2359858A1 (en) * | 2004-08-24 | 2011-08-24 | N.V. Nutricia | Nutritional composition comprising indigestible oligosaccharides |
| CN101099749A (en) * | 2007-07-25 | 2008-01-09 | 上海交大昂立股份有限公司 | Composition containing lactobacillus acidophilus and bidifobacterium longum and application thereof |
| CN101366734A (en) * | 2008-06-18 | 2009-02-18 | 辽宁大生药业有限公司 | Synbiotics medicament composition |
| US20120039956A1 (en) * | 2010-08-13 | 2012-02-16 | Moti Harel | Dry storage stabilizing composition for biological materials |
| CN103893219A (en) * | 2012-12-28 | 2014-07-02 | 瑞普（天津）生物药业有限公司 | Probiotics for preventing and treating pet diarrhea |
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| CN104548093A (en) * | 2014-12-22 | 2015-04-29 | 天津瑞普生物技术股份有限公司 | Composition for treating piglet diarrhea and preparation method of composition |
| CN107921113A (en) * | 2015-08-25 | 2018-04-17 | 巴比塔·阿格拉沃尔 | Immunomodulatory compositions and methods of use thereof |
| CN105125972A (en) * | 2015-09-21 | 2015-12-09 | 山西省农业科学院畜牧兽医研究所 | Chinese herbal preparation for improving intestinal microecology and repairing intestinal mucosa injuries of piglets |
| CN106729706A (en) * | 2015-11-19 | 2017-05-31 | 鼎正生物药业(天津)有限公司 | A kind of immune response regulation medicine based on IgG antibody |
| CN106806892A (en) * | 2015-12-02 | 2017-06-09 | 天津振邦水产养殖有限公司 | A kind of gut flora regulating drug based on Yolk antibody |
| CN106075433A (en) * | 2016-06-17 | 2016-11-09 | 山西纳安生物科技有限公司 | Many targeted nanos antibody polymerization chain junctor that a kind of probiotic bacteria that can be used for treatment of cancer is expressed |
| CN107296164A (en) * | 2017-07-19 | 2017-10-27 | 东北农业大学 | A kind of preparation method for the Traditional Chinese medicine probiotic fermentating metabolism product for preventing and treating piglet bacillary diarrhoea |
| CN108094726A (en) * | 2017-12-14 | 2018-06-01 | 福建傲农生物科技集团股份有限公司 | A kind of creep feed for enhancing pigling immunity and preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| IBRAHIM A.NAQID ET AL.: "Prebiotic and probiotic agents enhance antibody-based immune responses to Salmonella Typhimurium infection in pigs", 《ANIMAL FEED SCIENCE AND TECHNOLOGY》 * |
| 文英先: "卵黄抗体饲料添加剂在家禽生产中的应用", 《中国动物保健》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109385387A (en) * | 2018-12-28 | 2019-02-26 | 上海源耀生物股份有限公司 | The lactobacillus reuteri of anti-TGEV a kind of and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100581555C (en) | Viable prebiotics bacteria microcapsule preparations for livestock and method for preparing the same | |
| CA2601254C (en) | A method of improving intestinal flora in calves | |
| CN108103128A (en) | A kind of preparation method for the lactein for being used to treat grice diarrhoea | |
| CN104548093A (en) | Composition for treating piglet diarrhea and preparation method of composition | |
| CN103919816B (en) | A compound probiotic spray for preventing and treating neonatal livestock diarrhea and preparation method thereof | |
| US20140037605A1 (en) | Anticoccidial composition | |
| CN108888762A (en) | A kind of composition of the metabolite containing probiotics | |
| CN111821322A (en) | Poultry micro-ecological oral preparation capable of replacing antibiotics and application thereof | |
| CN111084155A (en) | Healthy breeding method for effectively preventing and controlling swine fever | |
| CN102754733A (en) | Novel micro-ecologic preparation for pig and preparation method thereof | |
| CN106359992A (en) | Seaweed additive aiming at diarrhea feed for piglets | |
| CN113967243B (en) | Fermented traditional Chinese medicine preparation for preventing and treating diarrhea of poultry and preparation method thereof | |
| JP2001224317A (en) | Feed composition | |
| JPH119196A (en) | Prevention of loss in livestock with chitosan | |
| CN106666150A (en) | Nonreactive health-care agent capable of improving production performance of breeding pigs and preparation method of nonreactive health-care agent | |
| CN106819470A (en) | Pig feed additive and its preparation method and application | |
| CN106666151A (en) | Antimicrobial-free additive for preventing and controlling piglet diarrhea and preparation method thereof | |
| CN113198014A (en) | Probiotic fermented traditional Chinese medicine compound immunoglobulin preparation and preparation method thereof | |
| RU2471359C1 (en) | Method for correction of immunobiological indices with piglets in period of weaning | |
| RU2432393C1 (en) | METHOD TO PRODUCE PROBIOTIC PREPARATION BASED ON SPOROGENOUS STRAINS Bac subtillis AND Bac licheniformis | |
| CN113577112B (en) | A kind of pharmaceutical composition for preventing and treating poultry salmonellosis and preparation method | |
| CN113244220A (en) | Application of potassium dehydroandrographolide succinate in preparation of veterinary drug for treating cow mastitis and potassium dehydroandrographolide succinate veterinary drug | |
| RU2691594C1 (en) | Composite feed biopolymer additive for imitating natural digestion processes with intensive growing of poultry and animals in agriculture and a method for production thereof | |
| RU2524664C1 (en) | Method of prevention of mass gastrointestinal and respiratory diseases of suckling pigs | |
| CN102068536B (en) | A compound traditional Chinese medicine granule and its application in the preparation of drugs for preventing and treating pig digestive tract diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181127 |